Brief: Sutro Biopharma Q3 Revenue USD 16.924 Million
13/11/2023 21:30
Nov 13 (Reuters) - Sutro Biopharma Q3 operating expenses USD 60.938 million. * Q3 basic EPS USD -0.81 * Q3 net income USD -49.284 million * Q3 operating income USD -44.014 million
Recent news on Sutro Biopharma
See all newsBrief: Sutro Biopharma Announces First Patient Dosed In Phase 1 Trial Of STRO-006
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte
Sutro Biopharma Inc reports results for the quarter ended June 30 - Earnings Summary
Sutro Biopharma tumbles after missing estimates